Literature DB >> 6597119

A novel human myelomonocytoid cell line, P39/Tsugane, derived from overt leukemia following myelodysplastic syndrome.

M Nagai, S Seki, T Kitahara, T Abe, K Minato, S Watanabe, M Shimoyama.   

Abstract

A novel human cultured cell line, P39/Tsugane, was established from leukemic cells in the peripheral blood of a 69-year-old male with overt leukemia following myelodysplastic syndrome (MDS). P39/Tsugane cells were characterized by blastic appearance, presence of NaF-sensitive alpha-naphthyl butylate esterase activity, Fc gamma-receptor, C3-receptor, capacity to phagocytize sensitized erythrocytes, and reactivity with monoclonal antibodies such as OKT4, My4, VIMD5, MCS-2 and My7. These data indicate that P39/Tsugane cells are of myelomonocytoid nature. P39/Tsugane had a hypodiploid chromosome constitution with a gain of a consistent marker, 6q+, the presence of less consistent markers 9q+ and rcp(14;16), and random and non-random losses of autosomes: in accordance with the reported cytogenetic profiles of MDS, a representative karyotype of the present cell line is 45,XY,+del(6)(q15),9q+, t(14;16)-(q24;q21),-16,-17. P39/Tsugane cells were transplantable intraperitoneally into nude mice, and produced abdominal tumors and hemorrhagic ascites. These results indicate that P39/Tsugane is the first cultured cell line of myelomonocytoid nature to be derived from overt leukemia following MDS. Therefore, P39/Tsugane cells should be useful for studies on the differentiation of leukemia cells, the pathogenesis of MDS and in vitro-in vivo experimental chemotherapy.

Entities:  

Mesh:

Year:  1984        PMID: 6597119

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  3 in total

1.  P39/Tsugane cells are a false cell line contaminated with HL-60 cells and are not suitable for mechanistic studies in myelodysplastic syndromes.

Authors:  David P Steensma
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

2.  Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.

Authors:  Laurie Freire Boullosa; Payalben Savaliya; Stephanie Bonney; Laurence Orchard; Hannah Wickenden; Cindy Lee; Evelien Smits; Alison H Banham; Ken I Mills; Kim Orchard; Barbara-Ann Guinn
Journal:  Oncotarget       Date:  2017-12-17

3.  Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.

Authors:  Hakan Savlı; Sara Galimberti; Deniz Sünnetçi; Martina Canesastraro; Giuseppe Palumbo; Balint Nagy; Francesco Di Raimondo; Mario Petrini
Journal:  Turk J Haematol       Date:  2015-09       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.